Latest Lamotrigine Stories
Lamictal Will Retain Decision Resources' Clinical Gold Standard Status for Bipolar Depression, According to a New Report from Decision Resources WALTHAM, Mass., April 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed psychiatrists identify a therapy's effect on decrease in severity of depressive symptoms as the attribute that most influences their prescribing decisions in bipolar...
According to a new study, children of mothers who took the epilepsy drug valproate during pregnancy had lower IQs than children of mothers who used other anti-seizure medications.
BRANFORD, Conn., March 3 /PRNewswire/ -- Marinus Pharmaceuticals, Inc. today announced that it met its primary endpoint for its Phase 2 clinical trial investigating the safety and efficacy of ganaxolone as adjunctive therapy in adults with partial onset seizures, a type of epilepsy.
PITTSBURGH, Jan. 28 /PRNewswire-FirstCall/ --Mylan Inc. (Nasdaq: MYL) today announced that its subsidiaries Mylan Pharmaceuticals Inc. and Genpharm ULC received final approvals from the U.S.
- Vimpat(R) demonstrated greater seizure reduction and improved seizure freedom versus placebo when added to first and second-generation antiepileptic drugs (AEDs) - Phase III study supports recent U.S. FDA and European Commission approvals of Vimpat(R) ATLANTA, Jan.
UCB's Keppra XR Will Become the Gold Standard Adjunctive Treatment for Partial-Onset Epilepsy by 2012, According to a New Report from Decision Resources WALTHAM, Mass., Jan.
However, AED Brands Facing Generic Competition Will be Dropped or Pushed to Tier Three of Many MCO Formularies, According to a New Report from Decision Resources WALTHAM, Mass., Jan.
The drugs that cure epileptic seizures are known to increase the risk of suicide, and federal regulators decided Tuesday drug companies must clearly display that warning.
- A poem in which the author retracts something said in an earlier poem.